



May 15, 2014

AnGes MG, Inc.

**Collategene® (DNA Plasmid with HGF Gene) Lymphedema Project  
Selected for NEDO's Venture Aid Program**

AnGes MG, Inc. ("AnGes") announced that the New Energy and Industrial Technology Development Organization (NEDO) has selected AnGes' Collategene® project "Clinical Development of Lymphedema Treatment Drug using HGF Plasmid" for its "2013 Venture Aid Program to Promote Practical Application of Innovation."

The venture aid program by NEDO is conducted under the Japanese government's supplementary budget of 2013 to support the development of advanced technology seeds or unutilized technologies held by research and development-based venture companies. It aims to generate new businesses and employment opportunities by reducing the risks of such companies, and by promoting prompt application and commercialization.

The Collategene® project selected by NEDO (which includes clinical trials) is a development project targeted to a practical application of innovative therapy for lymphedema. Lymphedema is an intractable disease where an impaired lymphatic system causes severe swelling and fluid retention in limbs by preventing lymphatic fluid from returning to lymph vessels. Existing treatments for lymphedema are only symptomatic and mainly focus on complex decongestive therapy, by massaging the affected limbs and using compression garments.

Hepatocyte Growth Factor (HGF) plasmid promotes the formation of new lymph vessels, and has the potential to become a definitive treatment. Development and practical application of this novel treatment for lymphedema is highly desired from a medical perspective.

This is the second time the Collategene® lymphedema project was selected for the grant from NEDO. The first was the "2012 Venture Aid Program to Promote Practical Application of Innovation" (subject period April 30, 2013 to February 20, 2014). AnGes started the Phase I/II study of Collategene® as a treatment for primary lymphedema in October 2013. Under the aid program, AnGes will continue development including the ongoing clinical trials.

AnGes will receive the grant, equivalent to two-thirds of the costs that will occur during the period subject to the program (May 2014 to February 2015). The grant money is expected

to be received during the fiscal year ending December 2015 and will have no effect on business performance for the fiscal year 2014.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGesMG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a></p>
--